Clinical trial
A Phase 1, Single-Blinded, Single-Ascending Dose Study to Evaluate the Safety and Tolerability of a Single Dose of LY3971297 in Participants With HFpEF and Participants With HFrEF
NCT07547540 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Single-Blinded, Single-Ascending Dose Study to Evaluate the Safety and Tolerability of a Single Dose of LY3971297 in Participants With HFpEF and Participants With HFrEF
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 11, 2026
- Completion date
- November 30, 2027
- Enrollment
- 90 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.